Bayer gets €3 billion in Apollo deal for LARC stake
10/07/2026 07:17
Bayer gets €3 billion in Apollo deal for LARC stake July 10 (Reuters) - Drugmaker Bayer BAYGn.DE has received €3 billion ($3.4 billion) in equity capital to improve capital structure after signing an agreement with global asset management firm Apollo APO.N, the German company said on Friday.
Bayer said that Apollo will gain a minority, non-controlling stake in its LARC business as part of the deal, which is expected to close in the third quarter.
($1 = 0.8741 euros)
(Reporting by Danny Callaghan; Editing by Emelia Sithole-Matarise)
((Email: danny.callaghan@thomsonreuters.com))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women